Clinical trial · Interventional
BRAF V600E Mutations In Papillary Thyroid Carcinoma
Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma
NCT01417442CI-TRIAL-00005372unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Papillary Thyroid Carcinoma | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BRAF V600E POSITIVITY | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BRAF V600E POSITIVITY
- description
- This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
- interventionNames
- Genetic: BRAF V600E POSITIVITY
Primary outcomes (1)
- measure
- BRAF V600E MUTATION
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with papillary thyroid cancer Exclusion Criteria: * Patients who do not want to be a part of this study
References
Publications (0)
Data not yet available
No reference posted for this study.